IQVIA Holdings faces growth challenges and softer demand, raising questions about its data-driven pharma enablement story

Earnings
โดย Simply Wall St·Read original
Summary · why it matters

IQVIA Holdings is under scrutiny as recent commentary highlights ongoing growth challenges, with revenue increases lagging peers and constant-currency trends pointing to softer demand and pressure on market share. The company's narrative projects $19.7 billion in revenue and $2.0 billion in earnings by 2029, requiring 5.8% yearly revenue growth and a roughly $0.6 billion earnings increase from $1.4 billion today. Some of the most pessimistic analysts already expected only about 5.4 percent annual revenue growth to roughly $19.5 billion and earnings near $1.8 billion by 2029, so this softer demand news could reinforce their concern that high leverage and slower growth might both worsen from here. IQVIA's May 2026 move to raise about $950 million in new senior notes to refinance existing debt is especially relevant, as elevated leverage and refinancing needs could collide with the capacity to keep investing in AI, data platforms, and higher-value services. The stock's fair value is estimated at $226.95, representing a 33% upside to its current price.

Impact on stocks 1

Biotech & Genomic Medicine · 1 stocks
IQVIA Holdings Inc
IQV
▼ NegativeDemandrelevance

Article highlights softer demand and revenue growth lagging peers, pressuring market share.